Shopping Cart 0
Cart Subtotal
USD 0

Fresenius Kabi AG - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
USD 750

Details

Summary

Fresenius Kabi AG (Fresenius Kabi), a wholly owned subsidiary of Fresenius SE & Co KGaA, develops, manufactures and markets pharmaceuticals products and medical devices. The company's product portfolio includes intravenously administered drugs, infusion therapy products, medical devices and clinical nutrition products. It covers therapeutic areas such as blood volume substitution, fluid management, anesthesia, critical illness, liver insufficiency, renal insufficiency, maldigestion or malabsorption, diabetes mellitus and pediatrics. Its products and services are used for the treatment of critically and chronically ill patients. Fresenius Kabi conducts sales and marketing operations through direct offices worldwide. The company has its facilities in Europe, North America, Latin America, Asia Pacific and Africa. Fresenius Kabi is headquartered in Bad Homburg, Germany.

Fresenius Kabi AG-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Fresenius Kabi AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Fresenius Kabi AG, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Fresenius Kabi AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Fresenius Kabi AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Fresenius Kabi AG, Medical Devices Deals, 2012 to YTD 2018 10

Fresenius Kabi AG, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Fresenius Kabi AG, Pharmaceuticals & Healthcare, Deal Details 12

Asset Purchase 12

Fresenius Kabi USA Acquires US Pharma Plant and Ready to Administer Drugs from Becton, Dickinson 12

Fresenius Kabi India To Acquire Manufacturing Unit Of Goa Formulations For USD 37 Million 13

APP Pharma Acquires Three Critical Care Products From Nexus Pharma 14

Partnerships 15

Otsuka Pharma Factory Enters Into Distribution Agreement With Fresenius Kabi Japan For HES Products 15

Provepharm Enters Into Distribution Agreement With Fresenius Kabi Pharma 16

Licensing Agreements 17

Medicines Company Enters Into Licensing Agreement With APP For Acute Care Generic Products 17

Caplin Point Laboratories Enters into Licensing and Distribution Agreement with Fresenius Kabi USA 18

InnoPharma Enters Into Licensing Agreement With Fresenius Kabi For Acetylcysteine Solution 19

Asset Transactions 20

Xellia Acquires Lyophilized Manufacturing Facility from Fresenius Kabi 20

Acquisition 21

NewCo Pharma Acquires CFL from Fresenius Kabi 21

Fresenius Kabi Acquires Novafarma Industria Farmaceutica 22

Fresenius Kabi Acquires 51% Stake in Ethica Industri Farmasi From Soho Global Halthcare 23

Fresenius Kabi (Singapore) To Delist Its Indian Arm 24

Linde To Acquire Calea France From Fresenius Kabi 25

Fresenius Kabi Completes Acquisition Of Fenwal From TPG Capital And Maverick Capital For USD 1.1 Billion 26

Fresenius Kabi Plans To Sell 15% Stake In Fresenius Kabi Oncology 28

Fresenius Kabi AG-Key Competitors 29

Fresenius Kabi AG-Key Employees 30

Fresenius Kabi AG-Locations And Subsidiaries 31

Head Office 31

Other Locations & Subsidiaries 31

Joint Venture 36

Recent Developments 37

Strategy And Business Planning 37

Oct 12, 2018: Fresenius Kabi opens compounding center in Canada 37

Jun 22, 2018: Fresenius Kabi UK expands operations in Runcorn, England 38

Nov 24, 2017: Fresenius Kabi opens production facility in Indonesia 39

Jul 06, 2017: Fresenius Kabi expands production site in Portugal 40

Financial Announcements 41

Oct 30, 2018: Fresenius in Q3/18 with continued strong Group earnings growth in constant currency 41

Feb 26, 2018: Fresenius remains on growth course after 14 straight record years 47

Nov 02, 2017: Fresenius reports another strong quarter and confirms guidance 54

Corporate Communications 56

Oct 10, 2017: Fresenius Kabi's Generic Drugs Business Unit Head elected as president of Medicines for Europe 56

Legal and Regulatory 57

Oct 01, 2018: Akorn comments on Delaware Chancery Court Ruling 57

May 28, 2018: New EU Commission's initiative SPC manufacturing waiver 58

Feb 26, 2018: Akorn Issues Statement on Investigation 59

Jan 29, 2018: HES solutions should remain on the market 60

Jan 03, 2018: USFDA issues warning letter to Fresenius Kabi for Baddi plant 61

Government and Public Interest 62

Nov 30, 2017: Statement by FDA Commissioner Scott Gottlieb, M.D., updating on Puerto Rico related medical product shortages 62

Other Significant Developments 63

Sep 08, 2017: Fresenius Kabi marks 20-year anniversary of Friedberg production site - Logistics center expansion planned 63

Mar 10, 2017: Fresenius Kabi builds new warehouse at Blonie production site 64

Appendix 65

Methodology 65

About GlobalData 65

Contact Us 65

Disclaimer 65


List Of Figure

List of Figures

Fresenius Kabi AG, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Fresenius Kabi AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Fresenius Kabi AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Fresenius Kabi AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Fresenius Kabi AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Fresenius Kabi AG, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Fresenius Kabi AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Fresenius Kabi AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Fresenius Kabi AG, Medical Devices Deals, 2012 to YTD 2018 10


List Of Table

List of Tables

Fresenius Kabi AG, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Fresenius Kabi AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Fresenius Kabi AG, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Fresenius Kabi AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Fresenius Kabi AG, Deals By Therapy Area, 2012 to YTD 2018 9

Fresenius Kabi AG, Medical Devices Deals, 2012 to YTD 2018 10

Fresenius Kabi AG, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Fresenius Kabi USA Acquires US Pharma Plant and Ready to Administer Drugs from Becton, Dickinson 12

Fresenius Kabi India To Acquire Manufacturing Unit Of Goa Formulations For USD 37 Million 13

APP Pharma Acquires Three Critical Care Products From Nexus Pharma 14

Otsuka Pharma Factory Enters Into Distribution Agreement With Fresenius Kabi Japan For HES Products 15

Provepharm Enters Into Distribution Agreement With Fresenius Kabi Pharma 16

Medicines Company Enters Into Licensing Agreement With APP For Acute Care Generic Products 17

Caplin Point Laboratories Enters into Licensing and Distribution Agreement with Fresenius Kabi USA 18

InnoPharma Enters Into Licensing Agreement With Fresenius Kabi For Acetylcysteine Solution 19

Xellia Acquires Lyophilized Manufacturing Facility from Fresenius Kabi 20

NewCo Pharma Acquires CFL from Fresenius Kabi 21

Fresenius Kabi Acquires Novafarma Industria Farmaceutica 22

Fresenius Kabi Acquires 51% Stake in Ethica Industri Farmasi From Soho Global Halthcare 23

Fresenius Kabi (Singapore) To Delist Its Indian Arm 24

Linde To Acquire Calea France From Fresenius Kabi 25

Fresenius Kabi Completes Acquisition Of Fenwal From TPG Capital And Maverick Capital For USD 1.1 Billion 26

Fresenius Kabi Plans To Sell 15% Stake In Fresenius Kabi Oncology 28

Fresenius Kabi AG, Key Competitors 29

Fresenius Kabi AG, Key Employees 30

Fresenius Kabi AG, Other Locations 31

Fresenius Kabi AG, Subsidiaries 33

Fresenius Kabi AG, Joint Venture 36

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Company Profile

Company Profile Title

Summary

Fresenius Kabi AG (Fresenius Kabi), a wholly owned subsidiary of Fresenius SE & Co KGaA, develops, manufactures and markets pharmaceuticals products and medical devices. The company's product portfolio includes intravenously administered drugs, infusion therapy products, medical devices and clinical nutrition products. It covers therapeutic areas such as blood volume substitution, fluid management, anesthesia, critical illness, liver insufficiency, renal insufficiency, maldigestion or malabsorption, diabetes mellitus and pediatrics. Its products and services are used for the treatment of critically and chronically ill patients. Fresenius Kabi conducts sales and marketing operations through direct offices worldwide. The company has its facilities in Europe, North America, Latin America, Asia Pacific and Africa. Fresenius Kabi is headquartered in Bad Homburg, Germany.

Fresenius Kabi AG-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Fresenius Kabi AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Fresenius Kabi AG, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Fresenius Kabi AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Fresenius Kabi AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Fresenius Kabi AG, Medical Devices Deals, 2012 to YTD 2018 10

Fresenius Kabi AG, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Fresenius Kabi AG, Pharmaceuticals & Healthcare, Deal Details 12

Asset Purchase 12

Fresenius Kabi USA Acquires US Pharma Plant and Ready to Administer Drugs from Becton, Dickinson 12

Fresenius Kabi India To Acquire Manufacturing Unit Of Goa Formulations For USD 37 Million 13

APP Pharma Acquires Three Critical Care Products From Nexus Pharma 14

Partnerships 15

Otsuka Pharma Factory Enters Into Distribution Agreement With Fresenius Kabi Japan For HES Products 15

Provepharm Enters Into Distribution Agreement With Fresenius Kabi Pharma 16

Licensing Agreements 17

Medicines Company Enters Into Licensing Agreement With APP For Acute Care Generic Products 17

Caplin Point Laboratories Enters into Licensing and Distribution Agreement with Fresenius Kabi USA 18

InnoPharma Enters Into Licensing Agreement With Fresenius Kabi For Acetylcysteine Solution 19

Asset Transactions 20

Xellia Acquires Lyophilized Manufacturing Facility from Fresenius Kabi 20

Acquisition 21

NewCo Pharma Acquires CFL from Fresenius Kabi 21

Fresenius Kabi Acquires Novafarma Industria Farmaceutica 22

Fresenius Kabi Acquires 51% Stake in Ethica Industri Farmasi From Soho Global Halthcare 23

Fresenius Kabi (Singapore) To Delist Its Indian Arm 24

Linde To Acquire Calea France From Fresenius Kabi 25

Fresenius Kabi Completes Acquisition Of Fenwal From TPG Capital And Maverick Capital For USD 1.1 Billion 26

Fresenius Kabi Plans To Sell 15% Stake In Fresenius Kabi Oncology 28

Fresenius Kabi AG-Key Competitors 29

Fresenius Kabi AG-Key Employees 30

Fresenius Kabi AG-Locations And Subsidiaries 31

Head Office 31

Other Locations & Subsidiaries 31

Joint Venture 36

Recent Developments 37

Strategy And Business Planning 37

Oct 12, 2018: Fresenius Kabi opens compounding center in Canada 37

Jun 22, 2018: Fresenius Kabi UK expands operations in Runcorn, England 38

Nov 24, 2017: Fresenius Kabi opens production facility in Indonesia 39

Jul 06, 2017: Fresenius Kabi expands production site in Portugal 40

Financial Announcements 41

Oct 30, 2018: Fresenius in Q3/18 with continued strong Group earnings growth in constant currency 41

Feb 26, 2018: Fresenius remains on growth course after 14 straight record years 47

Nov 02, 2017: Fresenius reports another strong quarter and confirms guidance 54

Corporate Communications 56

Oct 10, 2017: Fresenius Kabi's Generic Drugs Business Unit Head elected as president of Medicines for Europe 56

Legal and Regulatory 57

Oct 01, 2018: Akorn comments on Delaware Chancery Court Ruling 57

May 28, 2018: New EU Commission's initiative SPC manufacturing waiver 58

Feb 26, 2018: Akorn Issues Statement on Investigation 59

Jan 29, 2018: HES solutions should remain on the market 60

Jan 03, 2018: USFDA issues warning letter to Fresenius Kabi for Baddi plant 61

Government and Public Interest 62

Nov 30, 2017: Statement by FDA Commissioner Scott Gottlieb, M.D., updating on Puerto Rico related medical product shortages 62

Other Significant Developments 63

Sep 08, 2017: Fresenius Kabi marks 20-year anniversary of Friedberg production site - Logistics center expansion planned 63

Mar 10, 2017: Fresenius Kabi builds new warehouse at Blonie production site 64

Appendix 65

Methodology 65

About GlobalData 65

Contact Us 65

Disclaimer 65


List Of Figure

List of Figures

Fresenius Kabi AG, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Fresenius Kabi AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Fresenius Kabi AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Fresenius Kabi AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Fresenius Kabi AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Fresenius Kabi AG, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Fresenius Kabi AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Fresenius Kabi AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Fresenius Kabi AG, Medical Devices Deals, 2012 to YTD 2018 10


List Of Table

List of Tables

Fresenius Kabi AG, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Fresenius Kabi AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Fresenius Kabi AG, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Fresenius Kabi AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Fresenius Kabi AG, Deals By Therapy Area, 2012 to YTD 2018 9

Fresenius Kabi AG, Medical Devices Deals, 2012 to YTD 2018 10

Fresenius Kabi AG, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Fresenius Kabi USA Acquires US Pharma Plant and Ready to Administer Drugs from Becton, Dickinson 12

Fresenius Kabi India To Acquire Manufacturing Unit Of Goa Formulations For USD 37 Million 13

APP Pharma Acquires Three Critical Care Products From Nexus Pharma 14

Otsuka Pharma Factory Enters Into Distribution Agreement With Fresenius Kabi Japan For HES Products 15

Provepharm Enters Into Distribution Agreement With Fresenius Kabi Pharma 16

Medicines Company Enters Into Licensing Agreement With APP For Acute Care Generic Products 17

Caplin Point Laboratories Enters into Licensing and Distribution Agreement with Fresenius Kabi USA 18

InnoPharma Enters Into Licensing Agreement With Fresenius Kabi For Acetylcysteine Solution 19

Xellia Acquires Lyophilized Manufacturing Facility from Fresenius Kabi 20

NewCo Pharma Acquires CFL from Fresenius Kabi 21

Fresenius Kabi Acquires Novafarma Industria Farmaceutica 22

Fresenius Kabi Acquires 51% Stake in Ethica Industri Farmasi From Soho Global Halthcare 23

Fresenius Kabi (Singapore) To Delist Its Indian Arm 24

Linde To Acquire Calea France From Fresenius Kabi 25

Fresenius Kabi Completes Acquisition Of Fenwal From TPG Capital And Maverick Capital For USD 1.1 Billion 26

Fresenius Kabi Plans To Sell 15% Stake In Fresenius Kabi Oncology 28

Fresenius Kabi AG, Key Competitors 29

Fresenius Kabi AG, Key Employees 30

Fresenius Kabi AG, Other Locations 31

Fresenius Kabi AG, Subsidiaries 33

Fresenius Kabi AG, Joint Venture 36

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS